Form 4: Klaviyo Co-CEO Bialecki Reports Planned Stock Sales

Klaviyo Co-Chief Executive Officer Andrew Bialecki has filed a Form 4 detailing planned conversions and sales of Series A Common Stock under a Rule 10b5-1 trading plan.

Summary

• Andrew Bialecki, Co-Chief Executive Officer, Director, and 10% Owner of Klaviyo, Inc. (KVYO), reported planned transactions.
• These transactions, scheduled for March 17, 2026, are being executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025.
• The plan involves the conversion of 200,000 shares of Series B Common Stock into 200,000 shares of Series A Common Stock.
• Following the conversion, 200,000 shares of Series A Common Stock are planned to be sold in two tranches.
• The first tranche involves the sale of 97,379 Series A Common Stock at a weighted average price of $19.6 per share, with prices ranging from $19.33 to $20.32.
• The second tranche involves the sale of 102,621 Series A Common Stock at a weighted average price of $19.15 per share, with prices ranging from $19.10 to $19.32.
• After these planned transactions, Bialecki's direct beneficial ownership of Series A Common Stock from these specific transactions will be 0 shares.
• Bialecki continues to hold significant direct and indirect beneficial ownership of Series B Common Stock, totaling 68,144,118 directly and 8,074,640 indirectly through various trusts and his spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, it's pre-planned under a 10b5-1 plan, which mitigates negative sentiment, and the insider retains substantial ownership.

Positives

• The planned sales are executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to liquidity rather than an immediate reaction to market conditions.
• The reporting person retains substantial beneficial ownership of Series B Common Stock, convertible into Series A, demonstrating continued alignment with shareholder interests.

Negatives

• The planned sale of 200,000 shares by a Co-CEO, Director, and 10% owner could be perceived as a reduction in direct exposure to the company's publicly traded Series A stock.

Future Outlook

The filing indicates planned transactions for March 17, 2026, under a Rule 10b5-1 trading plan, suggesting a pre-determined schedule for the Co-CEO's stock liquidity.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are common for executives seeking to diversify their holdings and manage personal finances without being accused of trading on material non-public information. Such pre-scheduled sales are generally viewed as less indicative of management's sentiment about the company's immediate prospects compared to unscheduled, open-market sales.

Comparison to Industry Standards

• Insider sales through 10b5-1 plans are a standard practice among executives at publicly traded companies across various industries, including technology and software.
• Similar plans are frequently adopted by executives at companies like Salesforce (CRM) or HubSpot (HUBS) to manage their equity compensation.
• The volume of 200,000 shares represents a small fraction of Andrew Bialecki's total beneficial ownership, which includes over 68 million direct Series B shares, suggesting a routine diversification rather than a significant divestment.

Related Party Transactions

• The filing details indirect beneficial ownership through trusts where the reporting person or their spouse serves as trustee, which are considered related party holdings.

Stakeholder Impact

• Shareholders: The planned sale of 200,000 shares by a key executive could lead to a minor increase in the float of Series A Common Stock. However, given the pre-planned nature and the executive's retained substantial ownership, the impact on shareholder confidence is likely minimal.

Next Steps

• The planned transactions are scheduled to occur on March 17, 2026.

Key Dates

Recommendation

This Form 4 filing reports pre-scheduled insider sales under a 10b5-1 plan, which is a routine event for executives managing their equity compensation. It does not signal a change in the company's fundamentals or management's long-term outlook. The Co-CEO retains a very significant stake in the company through Series B shares. Therefore, this filing alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate, pending further fundamental analysis of Klaviyo's business performance.

Keywords

Klaviyo, KVYO, Andrew Bialecki, Form 4, insider trading, stock sale, 10b5-1 plan, Series A Common Stock, Series B Common Stock, Co-Chief Executive Officer, Director, 10% Owner